ALAIR.PA • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALAIR.PA in your mock portfolio yet.
The negative EPS and corresponding negative P/E ratio indicate that Mexedia Società Per Azioni S.B. is currently loss‑making. Without evidence of a clear path to profitability or strong revenue growth, the earnings profile is a material concern for equity holders. The stock therefore trades more on expectations and sentiment than on demonstrated earnings power.
Despite a 12.3% gain over the last month, the stock still trades slightly below its 200‑day moving average, suggesting it remains in a broader consolidation or mild downtrend. The RSI near 36 is below the neutral 50 level but not yet oversold, indicating modest negative momentum with some room for either further downside or a rebound. Overall, technicals are mixed: short‑term price strength versus a still‑weak longer‑term trend.
Social media followings are very small in absolute terms, and growth over the last 90 days is marginal, offering limited evidence of strong brand traction or rapidly expanding investor/customer interest. LinkedIn shows the highest follower count, which may indicate some professional awareness but not necessarily robust commercial momentum. Overall, alternative data currently provides a weak and largely inconclusive signal for the stock.
Mexedia Società Per Azioni S.B. shows a loss‑making financial profile with negative EPS and P/E, while technicals and alternative data are mixed and not strong enough to counterbalance earnings risk. The recent one‑month price rise is encouraging but occurs against a backdrop of weak profitability and only modest external traction. Overall, the setup leans bearish until there is clearer evidence of improving fundamentals or stronger demand signals.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: